GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy

Aya Shiraki, Jun-ichi Oyama*, Toshiyuki Nishikido and Koichi Node

Abstract

Background: Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; however, its counter-protective effects have also been suggested in patients with heart failure and the clear explanation for its mechanisms have not yet been offered.

Methods: The effects of GLP-1 analog on cardiac function and energy metabolism, especially glycemic and lipid metabolisms were elucidated using non-diabetic J2N-k hamsters which showed spontaneous dilated cardiomyopathy. J2N-k hamsters were treated with PBS (HF group), low-dose (HF-L group) or high-dose liraglutide (HF-H group).

Results: In failing heart, GLP-1 analog exerted further deteriorated cardiac function (e.g. positive and negative dP/dt; \( p = 0.01 \) and \( p = 0.002 \), respectively) with overt fibrosis and cardiac enlargement (heart/body weight, 5.7 ± 0.2 in HF group versus 7.6 ± 0.2 in HF-H group; \( p = 0.02 \)). The protein expression of cardiac muscles indicated the energy starvation status. Indirect calorimetry showed that failing hearts consumed higher energy and carbohydrate than normal hearts; moreover, this tendency was augmented by GLP-1 analog administration. Upon 10% glucose solution loading with GLP-1 analog administration (HF-H-G group) as complementary experiments, the cardiac function and fibrosis significantly ameliorated, whereas carbohydrate utilization augmented further and lipid utilization reduced more. The prognosis of HF-H-G group also significantly improved (\( p = 0.025 \)).

Conclusions: Glucagon-like peptide-1 analog caused the relative but desperate shortage of glycemic energy source for the failing cardiac muscles and it may restrict ATP synthesis, resulting in cardiac function deterioration. Therefore, appropriate energy supply and amount of carbohydrate intake should be carefully considered when administrating incretin-related drugs to patients with heart failure.

Keywords: GLP-1, Heart failure, Metabolism
However, surprisingly, heart failure (HF) increasingly occurred in patients treated with liraglutide [8] and DPP4 inhibitors in a large-scale clinical trial [9] and some meta-analyses [10, 11]. The mechanisms underlying the role of incretin-related drugs in precipitating HF remain unknown [12].

Therefore, this study aimed to investigate the effects and mechanisms of liraglutide on cardiac dysfunction using hamsters that spontaneously developed HF.

Methods

Experimental animals
Male cardiomyopathic (J2N-k; n = 8) and normal (J2N-n; n = 64) hamsters were purchased from Japan SLC Inc., Japan, at the age of 20–27 weeks. J2N-k hamsters were generated from BIO 14.6 hamsters, whose cardiomyopathy are caused by δ-sarcoglycan mutation and showed exacerbating cardiac function [13]. J2N-k has its origin in BIO 14.6, and thus both of two lineages are innately almost similar; however, CPK levels in J2N-k lineage were more rapidly elevated and showed 2 months shorter lifespan as compared with the BIO14.6 lineage. The average lifespan of J2N-k is about 37 weeks, and approximately 90% of the cause of death was HF. J2N-k hamsters are recognized as established model of dilated cardiomyopathy (DCM), with mutations also detected in patients with DCM [14]. These hamsters were randomized to receive PBS (HF group) or liraglutide (purchased from Novo nordisk pharma, Denmark). Alzet osmotic pumps (2006) contained about 230 μl of PBS or liraglutide were implanted at the age of 31 weeks. Liraglutide was administered at 20 μg/kg/day (HF-L group) or 100 μg/kg/day (HF-H group) concentrations for 42 days. In the energy-complementary experiments, 10% glucose solution was administrated to hamsters instead of drinking water for 31–37 weeks along with high-dose liraglutide treatment (HF-H-G group).

Measurement of cardiac functions and tissue sampling
All hamsters (37 weeks old) were anesthetized with 0.75 mg/kg medetomidine, 4 mg/kg midazolam, and 5 mg/kg butorphanol IP. After an echocardiographic evaluation, a catheter was inserted into the left ventricle to measure blood pressure in the LV. After cardiac function measurements, blood samples were collected, HbA1c was measured using Banalyst Ace (USIO INC. Japan), and the rest were stored at −80 °C. After weighing the hearts and lungs, samples were frozen in liquid nitrogen and stored at −80 °C or fixed with formalin.

Western blot analysis
The heart tissue was homogenized in RIPA buffer containing NaF, trypsin inhibitor, leupeptin, glycerophosphate, and orthovanadate. Samples of heart tissue lysate were resolved on SDS-PAGE according to a standard protocol. After being transferred to the membranes, the samples were immunoblotted with primary antibodies, followed by secondary antibodies conjugated to a horseradish peroxidase. Bands were revealed using ECL select western blotting detection reagents (GE Healthcare, Buckinghamshire, UK), and band density was quantified using the Image J software. The following primary antibodies were used: CD36 (#sc-9154) and actin antibodies (#sc-1616) were obtained from Santa Cruz biotechnology (Santa Cruz, CA). GLUT-4 antibody (#2213), cleaved caspase-3 antibody (#9661), phospho-AMPKα (Thr172) antibody (#2535), and LC3A/B (1/2) antibody (#12741), were purchased from Cell Signaling (Danvers, MA).

ATP measurement
An ATP measurement kit for tissue (TA-100; Toyo B-net, Tokyo, Japan) was used to measure the ATP concentration of heart tissues according to the manufacturer's protocol. The chemiluminescence by the luciferase reaction was used to measure ATP concentration.

FFA measurement
Serum samples were obtained without fasting. Serum FFA levels were measured using Free fatty acid fluorometric assay kit (700310, Cayman, MI, USA) according to manufacturer's instructions.

Quantification of collagen content in the heart tissue
For conventional light microscopy, hearts were fixed in 4% neutral buffered formaldehyde solution and embedded in paraffin. Sections (8-μm thick) were stained following the Sirius red staining procedure to detect collagens. Red area and whole heart muscle sections were quantified using Image J.

Respiratory analysis
ARCO-2000 (Arco system, Japan) was used to measure oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory quotient (RQ), carbohydrate (CHO) and fat (FAT) consumption. It consists of mass spectrometer for respiratory analysis and multi-process monitoring for small animals. After a few days of habituation, data were obtained every 2 min for 2 days. Data were divided into light and dark phases: light phase, 8:00 a.m. to 8:00 p.m., and dark phase, 8 p.m. to 8:00 a.m.

Statistics
Data comparison in each group was performed with one-way analysis of variance (ANOVA) or Student's t test with step-down method. Multiple comparisons data were
analyzed using the Bonferroni method after ANOVA for all pairwise comparisons. A $p$-value of $<0.05$ was deemed statistically significant. All statistical analyses were performed using the SPSS software.

**Results**

**Cardiac dysfunction is further exacerbated by administration of GLP-1 analog**

Table 1 shows the characteristics of healthy hamsters (J2N-n), those (J2N-k) developed genetically dilated cardiomyopathy (DCM) and HF, and those treated with low-dose (HF-L) or high-dose (HF-H) liraglutide. As regards interventions, J2N-k hamsters were treated with low-dose (HF-L group) or high-dose liraglutide (HF-H group). No statistically significant differences in body weight and heart rate among the three groups (HF, HF-L, and HF-H) of J2N-k hamsters; however, the heart/body weight was significantly higher in the HF-H group than those in the HF group. Positive $dP/dt$ (systolic function) and negative $dP/dt$ (diastolic function) were impaired in HF-H groups as compared with the HF group. The LV anterior wall thickness was significantly lower in HF-L and HF-H groups (Table 2). The representative heart samples and heart/body weight are shown in Fig. 1. The high liraglutide group exhibited further cardiac enlargement. Sirius red staining in the HF-H group disclosed significantly more severe fibrosis than that in the HF group ($p = 0.003$; Fig. 2). In Sirius red stain, fibrosis occurred more heavily in anterior-septal wall than in a posterior wall. This may be the one of the reasons for the differences of between anterior wall thickness and posterior wall thickness in this model.

Respiratory gas analysis at aged 32 weeks revealed a relatively high energy consumption and increased CHO and decreased FAT consumption in groups with HF (Fig. 3d, e). Increased CHO reliance was also higher RQ in the HF group (Fig. 3b). These results indicated higher demands for energetic substrate, especially CHO consumption at aged 32 weeks, which were compensated and relatively moderate in HF states and phases in the HF group. When using high-dose liraglutide, this tendency was more noticeable in the HF-H group, marking higher RQ and CHO consumption with lower FAT consumption.

### Table 1 Biometric and hemodynamic parameters of hamsters with normal heart and heart failure

|                          | Normal hamsters (J2N-n) | PBS treatment (J2N-k) | Low-dose liraglutide treatment (J2N-k) | High-dose liraglutide treatment (J2N-k) |
|--------------------------|-------------------------|-----------------------|----------------------------------------|----------------------------------------|
|                          | (n = 8)                 | (n = 14)              | (n = 12)                               | (n = 13)                               |
| **Biometry**             |                         |                       |                                        |                                        |
| Body weight, g           | 120 ± 4.8               | 111 ± 2.7             | 113 ± 2.1                              | 107 ± 2.8                              |
| Heart, g                 | 0.51 ± 0.22             | 0.63 ± 0.20           | 0.60 ± 0.02                            | 0.72 ± 0.04                            |
| Heart/BW, mg/g           | 43 ± 0.0                | 57 ± 0.2              | 53 ± 0.3                               | 67 ± 0.4*                              |
| Lungs, g                 | 0.75 ± 0.03             | 0.74 ± 0.04           | 0.62 ± 0.02                            | 0.85 ± 0.09                            |
| Lungs/BW, mg/g           | 5.8 ± 0.2               | 6.8 ± 0.4             | 5.5 ± 0.2                              | 7.9 ± 0.9                              |
| **Echocardiography**     |                         |                       |                                        |                                        |
| HR, beats/min            | 392 ± 18                | 376 ± 13              | 412 ± 17                               | 376 ± 19                               |
| LVEDD, mm                | 4.5 ± 0.1               | 7.5 ± 0.2             | 7.5 ± 0.2                              | 7.4 ± 0.1                              |
| LVESD, mm                | 2.5 ± 0.1               | 6.6 ± 0.2             | 6.4 ± 0.2                              | 6.3 ± 0.2                              |
| LV ejection, %           | 0.81 ± 0.01             | 0.31 ± 0.01           | 0.36 ± 0.02                            | 0.35 ± 0.02                            |
| LV FS, %                 | 0.45 ± 0.01             | 0.13 ± 0.01           | 0.15 ± 0.01                            | 0.15 ± 0.01                            |
| LV AW, mm                | 0.95 ± 0.02             | 0.81 ± 0.02           | 0.72 ± 0.02*                           | 0.67 ± 0.01*                           |
| LV PW, mm                | 1.02 ± 0.02             | 0.84 ± 0.02           | 0.81 ± 0.02                            | 0.79 ± 0.02                            |
| **Intracardiac pressure**|                         |                       |                                        |                                        |
| Positive $dP/dt$, mmHg/s | 5512 ± 539              | 3566 ± 235            | 3100 ± 310                             | 2501 ± 290*                            |
| Negative $dP/dt$, mmHg/s | −4119 ± 543             | −2669 ± 143           | −2425 ± 281                            | −1700 ± 171*                           |
| EDP, mmHg                | 8.65 ± 1.7              | 8.71 ± 2.4            | 12.5 ± 4.3                             | 13.8 ± 2.8                             |
| Max pressure, mmHg       | 132 ± 13                | 806 ± 4.2             | 81.9 ± 14                              | 66.1 ± 5.5                             |
| Min pressure, mmHg       | 4.5 ± 2.0               | 61 ± 2.0              | 9.3 ± 3.0                              | 9.4 ± 2.0                              |

All values are expressed as mean ± SEM

HR heart rate, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, FS fractional shortening, AW anterior wall, PW posterior wall, EDP end-diastolic pressure, FFA free fatty acid

Liraglutide treatment groups compared with the PBS treatment group by the step-down method. *$P < 0.05$
Differences in HbA1c and free fatty acid (FFA) concentration were not significant in each group, whereas they tended to increase in the HF group. The tendency of decreased HbA1c levels in HF-L and HF-H is shown in Fig. 4a. In the HF-H group, the FFA level was slightly decreased (Fig. 4b).

Western blotting of heart tissues revealed a tendency of increased cleaved caspase-3 in the HF group and further induction when using liraglutide. An autophagy marker, LC3 II/I, was upregulated in the HF group and even further induced in the HF-L and HF-H groups. In addition, glucose transporter-4 (GLUT-4) and CD36, the substrate glucose and fat transporters, respectively, did not change between the HF and N groups, which particularly increased with GLP-1 analog administration (Fig. 5).

The AMPK phosphorylation tended to be slightly upregulated in HF groups (Fig. 5e). An ATP content in the cardiac muscles is slightly decreased, although no significance was observed in all groups. The ATP content measurements showed a slightly decreased ATP level per gram of heart weight in the HF, HF-L, and HF-H groups (Fig. 5f); however, estimated ATP contents in the whole heart showed slight ATP up-regulation in HF and further increase in the HF-H group, which showed a quite similar tendency in energy consumption measurements in indirect calorimetry in Fig. 3a.

As a result, energy consumption and ATP synthesis were enhanced, which are also exerted in elevated VO2 when HF worsened, accompanied with increased CHO and decreased FAT consumption, which showed declined use of lipids as energy source; moreover, GLP-1 analog treatment augmented these phenomena. GLP-1 analog administration has been considered as the cause of remarkable changes in cardiac metabolism, which results in further HF deterioration.

Additional administration of glucose ameliorated GLP-1-induced cardiac deterioration
A hypothesis that cardiac deterioration was caused by energetic, especially glycemic, deficiency in a failing cardiac muscle due to the GLP-1 agonist has been set. Therefore, whether additional glucose supplementation improved cardiac function in hamsters to provide 10% glucose solution instead of drinking water along with high-dose liraglutide administration (HF-H-G group) is examined.

As a result, hamsters took 6.99 kcal/day from 10% glucose-free intake, and food consumption was decreased. Therefore, the total calorie intake was comparable (24.34 kcal in the HF-H-G group vs. 24.22 kcal in the HF-H-G group, Table 3).
Surprisingly, additional administration of glucose completely reversed cardiac enlargement (Fig. 6a), heart/body weight ratio (Fig. 6b 7.6 ± 0.3 in HF-H group vs. 5.1 ± 0.2 in HF-H-G group, \( p < 0.005 \)), lung/body ratio, and LV wall thickness (Table 2) without changing the total calorie intake. In regard to cardiac function, 10% glucose intake ameliorated fractional shortening (0.15% ± 0.01% in the HF-H group vs. 0.20% ± 0.01% in the HF-H-G group, \( p < 0.05 \)) and positive dP/dt (\( p < 0.05 \)). Sirius red staining showed that the rate of fibrosis significantly decreased in the 10% glucose intake group (Fig. 6c). The Kaplan–Meier survival curve showed 10% glucose addition to high-dose liraglutide administration saved the early lethality of J2N-K hamsters (Fig. 7). These effects were accompanied by increased HbA1c levels (3.7% ± 0.1% vs. 4.6% ± 0.0%, \( p < 0.005 \)) and body weight (107 ± 2.8 g vs. 120.2 ± 2.8, \( p < 0.005 \)), whereas FFA concentration was slightly lower without statistical significance than those administered with high-dose liraglutide without 10% glucose intake (HF-H group; Fig. 8). Thus, additional glucose loading prevented cardiac dysfunction amelioration using the GLP-1 analog.

Moreover, indirect calorimetry showed that the highest RQ (0.99 in light phase and 0.98 in dark phase) and CHO and lowest FAT consumption were considered reasonable for consistent total energy consumption in the HF-H group as observed in the HF-H-G group (Fig. 9). Western blotting analysis revealed that cleaved caspase-3 and LC3 II/I levels were significantly lower in the HF-H-G group than those in the HF-H group. In
contrast, GLUT-4 and CD36 expression levels in the HF-H-G group were further augmented than those in the high-dose liraglutide group without glucose (Fig. 10).

Based on these results, GLP-1 analog compulsorily augmented the glucose demand in failing hearts that already depend more on glucose rather than fatty acids. Therefore, cardiac function could be maintained when adequate glucose supply could meet the excessive glucose demand caused by liraglutide administration in failing hearts, which had been already over-demanding for carbohydrates.

Discussion
The major findings in this study were as follows: (1) GLP-1 analog exacerbated cardiac dysfunction and (2) adequate glucose loading as energy substrate prevented HF deterioration.

The energy starvation hypothesis as a cause of HF has been drawing renewed attention recently [15, 16]. Our study suggested that, in line with “An Engine Out of Fuel” hypothesis [16], the cardiac muscle treated with liraglutide showed energy-starved expression, increasing the LC3 II/I ratio that resulted in autophagy occurrence, recycling system against energy depletion.
Previous studies revealed that failing hearts reduced FFA uptake and oxidation and, in contrast, elevated the glucose uptake in advanced HF [17–19], which were supported in our study, as observed by the increased CHO/FAT consumption rate in dilated cardiomyopathy. Although the mechanism remains uncertain in failing hearts, metabolic preference of substrates has been generally considered to change from lipid utilization to carbohydrate utilization [16, 20], although several researches elucidated malnutrition expressing that lower levels of low-density lipoprotein (LDL) cholesterol were correlated with worse HF prognosis. Clinical researches clearly showed that the lower the cholesterol level, the worse the prognosis in patients with HF [21]. Although lipid-lowering therapy with HMG-CoA reductase is recommended for patients with acute myocardial infarction, poor nutrition has a worse outcome in patients with HF, and low LDL levels were associated with worse outcomes than those in high LDL levels, known as the “lipid paradox.” Impaired myocardial energy production is associated with decreased ATP and phosphocreatine concentrations. This depletion appears to result from mitochondrial oxidation compromise in both fatty acids and carbohydrates, accompanied with a compensatory increase in glucose uptake and glycolysis [20]. However, effects and metabolism of using anti-diabetic drugs on failing heart have not been sufficiently concluded in previous studies. In our study, the GLP-1 analog was found to augment the features of energetic states in HF, resulting in the upregulation of carbohydrate consumption and reduced lipid consumption.

Although liraglutide treatment compromised failing heart, it still exerts protective effects when adequate amount of carbohydrate was supplied to the hearts. High CHO consumption and high RQ were 0.99 in the light phase and 0.98 in the dark phase in liraglutide with adequate glucose group, resulting in the highest cardiac function performance as compared with all HF groups, including the PBS group. Increased glucose/fat rate but not total calories in energy substrate saved the failing heart from starvation, prevented fibrosis, cardiac muscle thinning, and heart enlargement. In regard to protein expression, GLUT-4, the main glucose transporter in cardiac muscles, was upregulated in this study. This result was consistent with other studies demonstrating that GLUT-4 was induced by DPP4 inhibitors and liraglutide in the cardiac tissues, effectively allowing glucose into the tissues [22, 23]. Our result is also compatible with reports from Ramirez et al. [24] that sitagliptin increased glucose assimilation in detriment of fatty acid.

Originally, GLP-1 is secreted from the intestines after a meal ingestion and responds to the high glucose concentration in the blood and ends up letting glucose into the muscles and liver [25]. GLP-1 analog augments metabolic reliance on glucose in cardiac muscles and other organs, increasing insulin concentration and GLUT-4 expression in tissues and insulin secretion from the pancreas [26]. Interestingly, Hausenloy et al. [27] reported that the cardioprotective effect of GLP-1 for myocardial infarction was glucose-dependent, and GLP-1 and sitagliptin, a DPP4 inhibitor, did not reduce the infarct size with abnormal glucose level of 5 mmol/l, but high glucose level of 11 mmol/l in ex vivo and > 7–8 mmol/l in vivo study. Our results are in consistent with their findings that the cardioprotective effect of GLP-1 may occur only when the glucose concentration level is high. Kyhl et al. also reported that liraglutide treatment lacked any favorable alterations after acute MI in non-diabetic rats [28], this result might be caused by expected relatively low to normal level of glucose concentration.

**Fig. 4** a Serum HbA1c and FFA levels in each group. No significant difference was observed among all HF groups, although HbA1c tended to decrease in HF and decrease further in the HF-L and HF-H groups. b The serum FFA concentration was more upregulated in the HF group than that in the N group, but it tended to decrease in the HF-H group despite more severe cardiac dysfunction, although it was not statistically significant. FFA free fatty acid.
In this study, dilated and weakened cardiac muscles exerted increased glucose dependency more than healthy hearts; moreover, glycemic reliance is much more reinforced by GLP-1 analog in a failing heart. Liraglutide-treated failing heart was considered to have glucose shortage as a fuel because of the fact that adequate glucose supply dramatically improved cardiac function and their early mortality. As HbA1c levels between high-dose liraglutide and PBS groups were not significant, no apparent hypoglycemia has occurred. However, there may have
been a relative shortage in failing hearts due to the shift in energy utilization from lipids to carbohydrates. In fact, liraglutide is clinically used against obesity for non-diabetic patients [29–31], and no severe hypoglycemia has been reported. Therefore, GLP-1 agonist is recognized to reduce the glucose levels only when in hyperglycemia such as immediately after the meal. When the blood glucose level is low, GLP-1 cannot stimulate insulin secretion and inhibit glucagon secretion to maintain normoglycemia [32]. Therefore, our findings do not support the idea that apparent hypoglycemia caused HF exacerbation. Failing cardiac muscle demand more glucose; furthermore, liraglutide may boost this glucose dependency

| Consumption amount | Food without liraglutide | Food with high-dose liraglutide and 10% glucose solution | Food without high-dose liraglutide and 10% glucose solution | Total |
|--------------------|--------------------------|--------------------------------------------------------|---------------------------------------------------------|-------|
| Food amount (g)/day| 6.24 g                   | 6.78 g                                                 | 4.80 g                                                  | 17.02 g |
| Food calorie (kcal)/day| 22.40 kcal               | 24.34 kcal                                             | 17.23 kcal                                              | 53.97 kcal |
| Intake volume (ml)/day| 17.47 ml                 | 17.47 ml                                               | 17.47 ml                                                | 52.41 ml |
| Intake glucose (g)/day| 1.75 g                   | 1.75 g                                                 | 1.75 g                                                  | 5.25 g  |
| Intake calorie (kcal)/day| 6.99 kcal                | 6.99 kcal                                               | 6.99 kcal                                               | 20.97 kcal |

Food is a certified diet at 359 kcal/100 g

**Table 3 Predicted consumption of calories from food and 10% glucose solution intake**

Fig. 6  An additional 10% glucose administration to the high-dose liraglutide group ameliorated cardiac dilation and fibrosis.  
**a** An image representing the cardiac long axis view.  
**b** Heart/body weight which indicates severity of heart failure, was clearly decreased in HF-H-G group.  
**c** Sirius red staining showed improved cardiac fibrosis by 10% glucose treatment in combination with high-dose liraglutide (n = 4). Representative images of anterior wall in short axis of the heart are shown (scale bar: 500 µm). *p > 0.05 vs. HF + high-dose liraglutide group. HF heart failure, HF-H-G heart failure + 10% glucose
in terms of RQ upregulation and CHO consumption in the high-dose liraglutide group.

In this study, the influence of food and drink intake quantity according to liraglutide use cannot be excluded. GLP-1 reportedly inhibits gastric motility and emptying and suppresses appetite with body weight and fat tissue loss [33]. However, energy intake was almost equal in all groups, and energy consumption was relatively higher in the liraglutide-treated group as compared with the HF group. Therefore, shortage of total energy intake was not the mechanism to explain the HF worsening in this experiment.

A concern on another important substrate for heart muscles and lipid regulation has been reported. Although CD36, a lipid transporter, was significantly upregulated in cardiac tissues treated with liraglutide that relatively reduced serum FFA levels, FAT consumption in gas analysis was reduced, suggesting that fat consumption was decreased in reality. In fact, when glucose was additionally administered, cardiac dysfunction improved. This implies that liraglutide induced GLUT-4 in cardiac muscles, and glucose was effectively and preferably used for cardiac fertilization.

Increase serum FFA is thought to correlate with HF severity caused by the hyperadrenergic state [16]; however, the relatively low FFA level was observed in failing hearts treated with high-dose liraglutide. GLP-1 is reported to act on enterocyte, the cell responsible for lipid absorption and chylomicron assembly and secretion. Activation of GLP-1R signaling including liraglutide rapidly lowers plasma concentration of ApoB, chylomicrons, and triglycerides in vivo [33, 34]. Therefore, low FFA levels may be caused by the inhibitive effects of liraglutide on lipid absorption and released into the blood. Hamsters treated with high-dose liraglutide might not be able to use fatty substrate due to suppressed absorption and smaller amount of fat intake in the HF-H-G group. This lipid substrate depletion in the body might be one of the reasons of increased glucose feasibility in the high liraglutide groups.

Another explanation can be made based on the Randle cycle hypothesis, known as the “glucose-fatty acid cycle” to describe the association between fuel flux and fuel selection in tissues. Originally, lipid utilization inhibits glucose metabolism in tissues and has been known to play a role in insulin resistance; therefore, glucose utilization has also been reported to inhibit lipid metabolism in muscles and vice versa, thereby increasing malonyl-CoA that signals glucose utilization and controls long-chain fatty acid entry and oxidation in the mitochondria [35]. In this article, we focused metabolism of heart muscles, however, liraglutide has pleiotropic effects in many organs such as digestive system, skeletal muscle and brain. We have to consider those extracardiac effects, especially liver and skeletal muscle, which have strong relations regarding glucose flow in the body. Reduced glucose production in liver and increased glucose uptake in skeletal muscle may cause the limitation of glucose use in the heart.

It is reported that liraglutide increases 6–10 bpm heart rate by stimulation of the sinus node, and it could be through sympathetic nervous system in patients [36]. In our experiments, however, we could not reproduce heart rate upregulation, it may be possibly caused by anesthesia which affects heart rate when we performed cardiac catheterization and echocardiogram to obtain data including heart rate.

We showed exacerbated fibrosis in liraglutide administration along with HF, contradicted reports also exist. Zhang et al. [37] demonstrated that liraglutide...
treatment attenuated angiotensin II-induced tissue fibrosis, Zhao [38] found liraglutide alleviates cardiac fibrosis in STZ-induced diabetic cardiomyopathy. These confictions might arise from the differences in animal model; pressure loaded hypertensive heart disease, high glucose and high fat induced cardiomyopathy and/or HF with reduced ejection fraction. Aoyama et al. also noted that DPP4 inhibition alleviates shortage of GLP-1 induced by thoracic aortic constriction (TAC) and reported its protective effect. However, TAC model is pressure loaded model with induced hypertrophy of the heart, difference of etiology compared to present study may result in different conclusion [39].

Certainly, diabetic patients have been known to be highly at risk of developing heart failure [40]. Most clinical articles reported that DPP-4 inhibitors and GLP-1 analogs are neutral for adverse effects on HF; however, several remarkable studies have already been reported, and results of recent

---

**Fig. 9** Respiratory gas was captured every 2 min in 32-week-old hamsters for 2 days. Average values of light and dark phases are shown in the graph [open bar: light phase, closed bar: dark phase (n = 6 in each group)].

- **a** Energy expenditure was similar for administration of high-dose liraglutide with/without 10% glucose; however, **b** RQ was significantly upregulated in the group with 10% glucose administration. **c** VO₂/BW in hamsters with heart failure treated with liraglutide with/without 10% glucose. Liraglutide administration emphasized RQ upregulation in hamsters with heart failure, indicating increased dependency on **d** carbohydrate as an energy substrate during liraglutide administration and thereby suggesting that glucose was efficiently metabolized as an energy source. In contrast, fat oxidation reduced with addition of 10% glucose. **RQ** respiratory quotient, **VO₂** oxygen consumption, **CHO** carbohydrate, **FAT** fat. *p > 0.05 vs. HF-H group.
large-scale clinical trials are attracting public attention. The SAVOR-TIMI53 trial resulted in increased hospitalization for HF due to saxagliptin use (hazard ratio [HR]: 1.27, 95% confidence interval [CI] 1.07–1.51). Although the TECOS study was completely neutral (HR: 1.00, 95% CI 0.83–1.20), DPP 4 inhibitor in the EXAMINE trial tended to increase the hospitalization for HF (HR: 1.19; 95% CI 0.90–1.58). Moreover, a population-based retrospective cohort study described that sitagliptin use was not associated with increased risk of hospitalization or death, but was associated with increased risk of HF-related hospitalization in T2DM patients with pre-existing HF [41].

GLP-1 receptor antagonists have been expected beneficial effects extend to the cardiovascular system [42, 43]. However, in the FIGHT trial, a randomized clinical trial that investigated whether liraglutide improves the prognosis in patients with advanced HF, the primary end-point was that liraglutide could not improve the mortality [8]. However, especially regarding death or rehospitalization for HF, GLP-1 analog tended to worsen (HR: 1.30; 95% CI 0.92–1.83), although no statistically significant difference was observed. No favorable effects were observed for advanced HF with reduced LVEF. Moreover, it might be some differences between DPP4 inhibitor and GLP-1 agonist in HF patients. In another clinical cohort study, which figured that the use of GLP-1 agonists was associated with an increased risk of HF hospitalization compared to DPP4 inhibitors [44].

In experimental studies, saxagliptin impairs cardiac contraction by inhibiting Ca\(^{2+}\)/calmodulin-dependent protein kinase II-phospholamban-sarcoplasmic reticulum Ca\(^{2+}\)-ATPase 2a axis and Na\(^{+}\)-Ca\(^{2+}\) exchanger function in Ca\(^{2+}\) extrusion [45]. Genetic DPP-4 depletion exhibits impaired cardiac function and accelerated cardiac fibrosis in TAC-operated high fat-fed mice [46]. Exendin-4, a GLP-1 receptor agonist, can increase the heart rate and blood pressure [47]. These findings may be complicit in malice.
Therefore, many studies including clinical trials are still investigating the possibility and mechanisms whether incretin-related drugs may deteriorate cardiac function; however, the truthful and precise mechanism remains to be clarified, and their potential association with serious adverse effects including HF still exists. In this study, carbohydrates and lipids were investigated as energy sources for the heart and showed that GLP-1 analog deteriorates cardiac function in failing hearts. Furthermore, the deterioration of HF has been clarified to be prevented by adequate glucose supplementation with liraglutide administration. Failing heart may shift from lipid to carbohydrate utilization, and incretin-related drugs may result in insufficient carbohydrate supply to the heart and fail to exert protective effects to the cardiac function.

Conclusions
In HF situations, energy metabolism in the heart has shifted from lipid to carbohydrate, and the administration of GLP-1 agonist causes further cardiac dysfunction. Furthermore, adequate glucose supplementation improved HF. The mechanisms are suggested as follows: (1) energy starvation occurred in the cardiac muscle by liraglutide administration, (2) cardiac function was improved because sufficient supplementation of carbohydrate satisfied increased energetic, especially glycemic demand from the failing heart treated with GLP-1 agonist. The mechanism behind the cardiac function deterioration when treated with GLP-1 analog is considered to be caused by imbalanced carbohydrate demand and supplementation in the heart. This study has limitations because these are animal model experiments, further clinical studies should be conducted. However, the results in this study elucidate the adverse effects of GLP-1 analog on failing heart and the importance of glycemic metabolisms as an energy source, especially when using anti-metabolic drugs. Therefore, the glycemic control in patients with HF need to be different from those in patients without HF.

Abbreviations
GLP-1: glucagon-like peptide-1; DPP4: dipeptidyl peptidase-4; HF: heart failure; VO₂: oxygen consumption; VCO₂: carbon dioxide production; CHO: carbohydrate; FAT: fat; FFA: free fatty acid; GLUT-4: glucose transporter-4.

Acknowledgements
Capturing images of WB was conducted at Analytical Research Center for Experimental Sciences, Saga University. We thank Riki rake Milhoko for appropriate advices about histological images.

Authors’ contributions
A5 designed the study, acquired and analyzed data, and wrote manuscript mainly. JO designed the study with acquiring and analysis data, and also participated in manuscript writing. HK and TN assisted in acquiring data. NK provided reagents and supervision. All authors read and approved the final manuscript.

Funding
This work was supported by incentive for promising investigator from Saga University.

Availability of data and materials
The used and/or analyzed datasets are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All experiments were performed according to the regulations of the Animal Research Committee of Saga University and the Guide for the Care and Use of Laboratory Animals (NIH publication, Institutional permission #24-043).

Consent for publications
Not applicable.

Competing interests
KN has received honoraria from Otsuka, Ono Pharmaceutical, Takeda Pharmaceutical, Eli Lilly Japan, Astellas, Daiichi Sankyo Healthcare, MSD, Boehringer Ingelheim Japan, Mitsubishi Tanabe Pharma; research grants from Terumo, Asahi Kasei, Astellas, Mitsubishi Tanabe Pharma, Teijin Pharma; scholarships from Bayer Yakuhin, Daiichi Sankyo Healthcare, Teijin Pharma. The other authors declare that they have no competing interests.

Received: 7 August 2019 Accepted: 10 November 2019
Published online: 28 November 2019

References
1. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221(2):375–82.
2. Ravassa S, Zudaire A, Dise J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012;94(2):316–23.
3. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9.
4. Manso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(19):1519–29.
5. Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N, Lingvay I, Rosestri J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilssbøll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
6. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes: a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.
7. Andrikou E, Tsoufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N, GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol. 2018. https://doi.org/10.1016/j.hjcc.2018.11.008.
8. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kieran MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–8.
9. Scirica BM, Braunwald E, Raz I, Lavender MA, Morrow DA, Jularim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88.

10. Monami M, Dicembirini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–97.

11. Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Circ Thier. 2014;134(12):2072–9.

12. Zannad F, Rossignol P. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure. Circulation. 2019;139(3):362–5.

13. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyooka T, Hanaoka F. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA. 1997;94(18):13873–8.

14. Luk A, Ahn E, Soor GS, Butany J. Dilated cardiomyopathy: a review. J Clin Pathol. 2009;62(3):219–25.

15. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95(2):135–45.

16. Heusch G, Libby P, Gersh B, Yellow D, Böhm M, Lopaschuk G, Opie L. Cardiomyocytes remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933–43.

17. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002;106(5):606–12.

18. Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(2):171–7.

19. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, Gastaldi A, Egido J, Tuñón J, Morcillo MA, Lorenzo Ó. Sitagliptin improved glucose homeostasis and prolongs survival in a murine model of high-fat diet-induced obesity. Cardiovasc Diabetol. 2013;12:154.

20. Lopaschuk GD. Metabolic modulators in heart disease: past, present, and future. Can J Cardiol. 2017;33(7):838–49.

21. Lu YW, Lu SF, Chou RH, Wu PS, Ku YC, Kuo CS, Chang CC, Tsai YL, Wu CH, Huang PH. Lipid paradox in patients with acute myocardial infarction: potential impact of malnutrition. Clin Nutr. 2018;38:2311–8.

22. Gannucco G, Oliveira KC, Crajoinas RO, Venturini G, Salles TA, Fonseca-Alansiz MH, Maciel RM, Girardi AC. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol. 2013;698(1–3):74–86.

23. Noyan-Ashraf MH, Shikatani EA, Schulli I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Bilia F, Drucker DJ, Husain M. A glucagon-like peptide-1 antagonist reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127(1):74–85.

24. Ramirez E, Picatoste B, González-Bris A, Oteo M, Cruz F, Caro-Vadillo A, Ramírez E, Higueras A, Sinal L, Méndez R, Murgui T, Pascual A, Egido J, Tuñón J, Castellari M, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002;106(5):606–12.

25. Vyas AK, Yang KC, Woo D, Tzeckov A, Kovacs A, Jay PY, Hruz PW. Exendin-4 improves glucose homeostasis and prolongs survival in a murine model of high-fat diet-induced obesity. PLoS ONE. 2011;6(2):e17178.

26. Li Z, Ni CL, Yao Z, Chen LM, Niu WY. Li, Zannad F, Rossignol P. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–97.

27. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L. Weight maintenance and additional weight loss with lixivtaglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443–51.

28. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempef M, Lai DC, Le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of lixivtaglutide in weight management. N Engl J Med. 2015;373(1):11-22.

29. Nauck MA, Kleine N, Orsikov C, Holst JJ, Wills B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.

30. Russo GT, Labate AM, Gialdalia A, Romeo EL, Villari P, Alibrandi A, Perdichizzi G, Cinucitova D. Twelve-month treatment with Liraglutide alleviates Eccentric Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2015;38(1B):81–9.

31. Drucker DJ. The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications. Diabetes. 2018;67(9):1710–9.

32. Huang PH. Lipid paradox in patients with acute myocardial infarction: potential impact of malnutrition. Clin Nutr. 2018;38:2311–8.

33. Monami M, Dicembirini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–97.

34. Fuentes. 2017;93:1–12.

35. Oswald JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002;106(5):606–12.

36. Heusch G, Libby P, Gersh B, Yellow D, Böhm M, Lopaschuk G, Opie L. Cardiomyocytes remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933–43.

37. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, Gastaldelli A, Cioccio D, Pellegrini P, Testa R, Menichelli L, Abbate A, Stanley WC, Recchia FA. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;293(6):H3270–8.

38. Lopaschuk GD. Metabolic modulators in heart disease: past, present, and future. Can J Cardiol. 2017;33(7):838–49.

39. Lu YW, Lu SF, Chou RH, Wu PS, Ku YC, Kuo CS, Chang CC, Tsai YL, Wu CH, Huang PH. Lipid paradox in patients with acute myocardial infarction: potential impact of malnutrition. Clin Nutr. 2018;38:2311–8.

40. Zannad F, Rossignol P. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–97.

41. Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Circ Thier. 2014;134(12):2072–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.